FDA Approves Abrysvo for RSV Prevention in Adults 18-59 at Increased Risk
Key Insights
The FDA has approved Pfizer's Abrysvo vaccine for preventing RSV (search)-associated lower respiratory tract disease in adults aged 18-59 at increased risk.
Abrysvo is the first and only RSV (search) vaccine indicated for adults younger than 50 years old, offering a new preventive option.
A study highlights the importance of COVID-19 (search) vaccination in preventing hospitalizations among children, especially with emerging variants.
Pfizer's Abrysvo vaccine has received FDA approval for the prevention of respiratory syncytial virus (search) (RSV (search))-associated lower respiratory tract disease in individuals aged 18 to 59 who are at increased risk of disease. This approval marks a significant advancement in preventative medicine, offering the first and only RSV vaccine option for adults under 50.
Abrysvo: A Novel RSV Vaccine
Abrysvo is an unadjuvanted, bivalent RSV (search) prefusion F (RSVpreF) vaccine designed to protect against RSV, a common respiratory virus that can lead to severe illness, particularly in vulnerable populations. The vaccine's approval expands the scope of RSV prevention to include younger adults at increased risk, addressing a previously unmet need.
COVID-19 Vaccination and Pediatric Hospitalizations
Emerging data continue to underscore the importance of vaccination in preventing severe outcomes from COVID-19 (search), especially in children. A recent study published in Influenza (search) and Other Respiratory Viruses found that younger children ineligible for vaccination face a higher risk of hospitalization due to COVID-19. The study also noted that while older children had a lower risk of hospitalization, they often required a higher level of care when hospitalized, reinforcing the protective benefits of vaccination.
Immunization Efficacy and Antibiotic Use in Pediatrics
Presentations at IDWeek 2024 highlighted the effectiveness of influenza (search), pneumococcal conjugate, and mpox (search) vaccines in safeguarding children from these diseases. The research indicated that vaccine administration was associated with a reduction in annual antibiotic prescriptions among study participants, suggesting a broader benefit of immunization in reducing antibiotic use and combating antimicrobial resistance.
Disparities in Post-Surgical Analgesia
Research presented at ANESTHESIOLOGY 2024 revealed potential disparities in access to multimodal analgesia for Black patients following major surgery compared to white patients. These findings underscore the need for equitable pain management strategies and further investigation into factors contributing to these disparities.